Abstract Library

#2753 Risk of PRRT-Associated Bowel Obstruction in Patients with Mesenteric/Peritoneal Disease and Potential Role of Corticosteroids in Treatment

Introduction: Although radiation-induced mesenteritis or peritonitis can potentially exacerbate risk of bowel obstruction, there are no data in the literature on incidence of intestinal obstruction related to peptide receptor radiotherapy (PRRT)

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Al-Toubah T, El-Haddad G, Pelle E, Strosberg J,

Keywords: PRRT, Lutetium-dotatate, Bowel obstruction, Peritoneal carcinomatosis, Steroids,

#2120 One Year Experience with Lutetium-DOTATATE for Disseminated NETs in the Gregorio Marañon Hospital

Introduction: The main curative therapy for NET is surgical resection when the disease is localized. But high percentage of patients is diagnosed with advanced disseminated disease and the peptide receptor radionuclide therapy (PRRT) with somatostatin analogs (SSA) is an emerging effective treatment.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Picallo P

Authors: Picallo M, Percovich J, García Centeno R, Rotger A, Colon A,

Keywords: Neuroendocrine, Lutetium, Radionuclide therapy,

#287 Lutetium-177 DOTATATE Therapy in the Management of Neuroendocrine Tumors

Introduction: Peptide receptor radionuclide therapy (PRRT) is a specific targeted treatment for NETs expressing somatostatin receptors. 177Lu-DOTATATE is one of several newly available compounds for this treatment.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Carroll R, Tan T, Todd J, Al-Nahhas A, Bomanji J,

Keywords: 177Lutetium-DOTATATE therapy, neuroendocrine tumor, paraganglioma, SDHB,